Hard on the heels of Regeneron moving its COVID-19 antibody cocktail into late-stage testing, the US government has agreed a deal to ramp up manufacturing – and claim the first doses to be made.
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
Regeneron has said it has begun clinical trials of its antibody cocktail therapy for COVID-19, as pharma companies continue their search for treatments as the pandemic continues to cause havoc ...
GlobalData on MSN12d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoidAs Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...
Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...
Regeneron's gene therapy study shows improved ... 2024 US FDA revokes authorization for four COVID antibody drugs The U.S. Food and Drug Administration has revoked the emergency use authorization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback